TerminatedPhase 3NCT01555333

An Open Label Extension Study in Subjects With Fragile X Syndrome

Studying Fragile X syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Seaside Therapeutics, Inc.
Principal Investigator
Paul Wang, M.D.
Seaside Therapeutics, Inc.
Intervention
arbaclofen(drug)
Enrollment
357 enrolled
Eligibility
5-50 years · All sexes
Timeline
2011 – 2013

Study locations (23)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01555333 on ClinicalTrials.gov

Other trials for Fragile X syndrome

Additional recruiting or active studies for the same condition.

See all trials for Fragile X syndrome →

← Back to all trials